Novo Nordisk 4Q10 4Q Revenues: $2.9 billion (+14%) 4Q Earnings: $720 million (+56%) FY Revenues: $10.9 billion (+13%) FY Earnings: $2.6 billion (+27%) Comments: Diabetes care revenues for FY were $8.1 billion (+16%), while FY Biopharma revenues were up 5% to $2.7 billion. Modern insulins were up 18% for $4.7 billion in revenues during the year. Sales of Victoza, a GLP-1 therapy for type 2 diabetes, posted $413 million in FY revenues. Earnings in 4Q10 and FY were boosted by $200 mi...